

Evolution and Spread of a Multidrug-Resistant *Proteus mirabilis* Clone with Chromosomal AmpC-Type Cephalosporinases in Europe[∇]

M. M. D'Andrea,^{1†} E. Literacka,^{2†} A. Zioga,^{3†} T. Giani,¹ A. Baraniak,² J. Fiett,² E. Sadowy,²
P. T. Tassios,⁴ G. M. Rossolini,¹ M. Gniadkowski,^{2*} and V. Miriagou³

Department of Molecular Biology, Section of Microbiology, University of Siena, Siena, Italy¹; National Medicines Institute, Warsaw, Poland²; Hellenic Pasteur Institute, Athens, Greece³; and Department of Microbiology, Medical School, University of Athens, Athens, Greece⁴

Received 14 December 2010/Returned for modification 28 January 2011/Accepted 3 March 2011

Proteus mirabilis isolates obtained in 1999 to 2008 from three European countries were analyzed; all carried chromosomal AmpC-type cephalosporinase *bla*_{CMY} genes from a *Citrobacter freundii* origin (*bla*_{CMY-2}-like genes). Isolates from Poland harbored several *bla*_{CMY} genes (*bla*_{CMY-4}, *bla*_{CMY-12}, *bla*_{CMY-14}, *bla*_{CMY-15}, and *bla*_{CMY-38} and the new gene *bla*_{CMY-45}), while isolates from Italy and Greece harbored *bla*_{CMY-16} only. Earlier isolates with *bla*_{CMY-4} or *bla*_{CMY-12}, recovered in France from Greek and Algerian patients, were also studied. All isolates showed striking similarities. Their *bla*_{CMY} genes resided within *ISEcp1* transposition modules, named Tn6093, characterized by a 110-bp distance between *ISEcp1* and *bla*_{CMY}, and identical fragments of both *C. freundii* DNA and a ColE1-type plasmid backbone. Moreover, these modules were inserted into the same chromosomal site, within the *pepQ* gene. Since ColE1 plasmids carrying *ISEcp1* with similar *C. freundii* DNA fragments (Tn6114) had been identified earlier, it is likely that a similar molecule had mediated at some stage this DNA transfer between *C. freundii* and *P. mirabilis*. In addition, isolates with *bla*_{CMY-12}, *bla*_{CMY-15}, and *bla*_{CMY-38} genes harbored a second *bla*_{CMY} copy within a shorter *ISEcp1* module (Tn6113), always inserted downstream of the *ppiD* gene. Sequence analysis of all mobile *bla*_{CMY-2}-like genes indicated that those integrated in the *P. mirabilis* chromosome form a distinct cluster that may have evolved by the stepwise accumulation of mutations. All of these observations, coupled to strain typing data, suggest that the *bla*_{CMY} genes studied here may have originated from a single *ISEcp1*-mediated mobilization-transfer-integration process, followed by the spread and evolution of a *P. mirabilis* clone over time and a large geographic area.

Acquired cephalosporinases of the AmpC type constitute a significant source of resistance to most of the newer-generation β-lactams in *Enterobacteriaceae* (3, 18, 29). Similar to their natural precursors in several Gram-negative species, e.g., *Aeromonas* spp., *Enterobacter* spp., *Morganella morganii*, or *Citrobacter freundii*, these enzymes hydrolyze penicillins, most cephalosporins, and aztreonam and are poorly inhibited by β-lactam inhibitors (5, 18). Usually, acquired AmpCs are expressed constitutively, conferring resistance to all of their substrates and inhibitor combinations, although resistance levels depend on the amounts of enzymes produced, as well as the presence of other resistance mechanisms (18, 29). The acquired *ampC* genes have escaped from the chromosome of some species to plasmids, following mobilizations mediated by such elements as IS26, *ISEcp1*, or *ISCR1* (14, 21, 24, 27, 34). The identity of these elements, their location with respect to the *ampC* gene, and the size of the DNA fragment mobilized are diagnostic of specific escape events. Mobilizations of the *C. freundii ampC* have given rise to *bla*_{CMY} genes observed in many species worldwide (1, 18, 29). With more than 40 genes identified thus far in this family, in which *bla*_{CMY-2} is the most common, this is the largest group of mobile *ampCs* (18, 29).

*bla*_{CMY-2} may also be the precursor of other *bla*_{CMY} genes through the accumulation of neutral mutations (1).

ISEcp1 has played an important role in mobilizing *bla*_{CMY-2}-like genes, since it is often found at their 5' flanks (14, 21, 23, 26, 32). It may transpose together with adjacent DNA fragments on the 3' side, producing transposition modules of various sizes. This process utilizes sequences similar to the *ISEcp1* inverted right repeat (IRR), and such alternative IRRs mark precisely the modules' 3' ends (20). *ISEcp1* has been identified 116 bp upstream from *bla*_{CMY-2}, *bla*_{CMY-4}, *bla*_{CMY-7}, *bla*_{CMY-21}, and *bla*_{CMY-23} genes in plasmids of the IncA/C and IncI1 groups disseminated worldwide among *Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella enterica*, and *Proteus mirabilis* (14–16, 26, 32, 36, 37). It has also been found 110 bp upstream from *bla*_{CMY-5}, *bla*_{CMY-31}, and *bla*_{CMY-36} genes in highly similar ColE1-type plasmids in *Klebsiella oxytoca* (pTKH11), *S. enterica* serovar Newport (pA172), and *K. pneumoniae* (pH 205) from Sweden, the United States, and Greece, respectively (38, 39).

Chromosomal *bla*_{CMY} genes (*bla*_{CMY-3}, *bla*_{CMY-4}, and *bla*_{CMY-12}) in *P. mirabilis* were first observed sporadically in France, in patients with Greek and Algerian origins (4, 11). Later, *P. mirabilis* isolates with *ISEcp1* close to *bla*_{CMY-2}-like genes in their chromosome were also found in Poland (*bla*_{CMY-4}, *bla*_{CMY-12}, *bla*_{CMY-14}, *bla*_{CMY-15}, and *bla*_{CMY-38}) (13, 21), Italy (*bla*_{CMY-16}) (9, 23), and Greece (25). The present international molecular epidemiology study aimed to compare all of the above *P. mirabilis* isolates, in order to assess the clonality of *bla*_{CMY-2}-like gene sequences, their transposition

* Corresponding author. Mailing address: National Medicines Institute, ul. Chelmska 30/34, 00-725 Warsaw, Poland. Phone: (48) 22-851 43 88. Fax: (48) 22-841 29 49. E-mail: gniadkow@cls.edu.pl.

† M.M.D., E.L., and A.Z. contributed equally to this study.

∇ Published ahead of print on 14 March 2011.

TABLE 1. *P. mirabilis* isolates: basic information from previous studies and the present study

Strain	Yr of isolation ^a	Country	City	Specimen	CMY variant	Other β -lactamase(s)	ISEcp1 modules	Ribotype	Source or reference
PL 6735/99	1999	Poland	Warsaw	Urine	CMY-14	TEM-1	Tn6093	R5	21
PL 1662/00	2000	Poland	Warsaw	Pus	CMY-15	TEM-2	Tn6093, Tn6113	R5	21
PL 27/00	1999	Poland	Grajewo	Urine	CMY-12	TEM-2	Tn6093, Tn6113	R5	21
PL 1376/00	2000	Poland	Zielona Góra	Urine	CMY-45	TEM-1	Tn6093	R6	This study
PL 864/01	2001	Poland	Lublin	Sputum	CMY-4	TEM-1	Tn6093	R5	21
PL 1455/04	2004	Poland	Łódź	Urine	CMY-38	TEM-2	Tn6093, Tn6113	R5	13
IT NO-051/03	2003	Italy	Novara	Cutaneous ulcer	CMY-16	TEM-1	Tn6093	R5	9
IT VA-1017/03	2003	Italy	Varese	Urine	CMY-16	TEM-1	Tn6093	R5	9
IT VA-832/05	2005	Italy	Varese	Urine	CMY-16	TEM-1	Tn6093	R5	23
IT VA-070/06	2006	Italy	Varese	Urine	CMY-16	TEM-1	Tn6093	R5	23
IT VA-414/06	2006	Italy	Varese	Urine	CMY-16	TEM-1	Tn6093	R5	23
IT LC-10/08	2008	Italy	Lecco	Blood	CMY-16	TEM-1	Tn6093	R5	This study
GR 17/04	2004	Greece	Thessaloniki	Urine	CMY-16	VIM-1, TEM-1	Tn6093	R5	35
GR 15184/05	2005	Greece	Thessaloniki	Urine	CMY-16	VIM-1, TEM-1	Tn6093	R5	35
GR 15315/05	2005	Greece	Thessaloniki	Urine	CMY-16	VIM-1, TEM-1	Tn6093	R5	35
GR 2506/07	2007	Greece	Athens	Sputum	CMY-16	VIM-1, TEM-1	Tn6093	R5	This study
GR 2530/07	2007	Greece	Athens	Urine	CMY-16	VIM-1, TEM-1	Tn6093	R5	This study
GR 2720/08	2008	Greece	Athens	Sputum	CMY-16	VIM-1, TEM-1	Tn6093	R5	25
22317	–	France/Greece	Paris	Bile	CMY-4	TEM-1	Tn6093	R7	11
PLAR	–	France/Greece	Paris	Feces	CMY-4	TEM-1	Tn6093	R7	11
34955	–	France/Algeria	Paris	Urinary catheter	CMY-12	TEM-2	Tn6093, Tn6113	R5	11
GR-485-S	2007	Greece	Athens	Urine	No	None	No	R4	This study
GR-20A-S	2007	Greece	Athens	Urine	No	None	No	ND ^b	This study
GR-99-S	2007	Greece	Athens	Pus	No	None	No	R1	This study
GR-106-S	2007	Greece	Athens	Pus	No	None	No	R1	This study
GR-20-S	2008	Greece	Athens	Pus	No	None	No	R2	This study
GR-28-S	2008	Greece	Athens	Pus	No	None	No	R2	This study
GR-59-S	2008	Greece	Athens	Sputum	No	None	No	R3	This study

^a –, The date of isolation was not provided in the reference paper (11).

^b ND, not determined.

modules, and insertion regions, as well as of the bacterial chromosomes themselves.

MATERIALS AND METHODS

Bacterial strains. Twenty-one CMY-producing *P. mirabilis* isolates were studied (Table 1). Eighteen had been recovered between 1999 and 2008 in hospitals of different cities of Poland, Greece, and Italy and were selected (six isolates per country) from larger groups of isolates partially described previously (9, 13, 21, 23, 25, 35). The Polish isolates belonged to various pulsed-field gel electrophoresis (PFGE) patterns and harbored all of the *bla*_{CMY} genes identified in *P. mirabilis* in that country thus far; the Italian and Greek isolates represented different PFGE patterns and/or clinical centers where these organisms have been studied to date. The three remaining *P. mirabilis* strains with chromosomal *bla*_{CMY}s, kindly provided by G. Arlet, were isolated in hospitals in Paris from patients originating either from either Greece or Algeria. Strains 22317 and PLAR (Greece) were among the earliest CMY-4 producers reported, while strain 34955 (Algeria) was the first CMY-12 producer ever identified (11). Seven AmpC-negative, epidemiologically unrelated *P. mirabilis* isolates were included for comparative typing; these had been collected from different Greek hospitals from 2006 to 2008.

Detection and sequencing of *bla*_{CMY} genes. The entire coding regions of *bla*_{CMY} genes were amplified with the primers ampC1 and ampC2 (11) and directly sequenced by using several *bla*_{CMY}-specific primers (Table 2). *bla*_{CMY} sequences were compared for evolutionary relationships by using the MEGA v3.1 software (19). Subsequently, the sequences, prealigned in Mauve 2.3.0 (10), were analyzed by using CloneFrame 1.1 software (12), and the results were visualized by using SplitsTree 4.10 (17) as a consensus network. DNA sequencing in all experiments of the present study was performed either in-house, using the Applied Biosystems technology and equipment (Foster City, CA), or by an external facility (Macrogen, Inc., Seoul, Korea).

Detection of the ISEcp1 element. The ISEcp1 element was detected upstream of *bla*_{CMY} genes by PCR with the primers ecpF2 and ampC5 (Table 2), which were also used for sequencing the spacer region between ISEcp1 and the *bla*_{CMY} genes.

Assays of *bla*_{CMY} locus number and localization. The number of loci containing *bla*_{CMY} genes was assessed by hybridization of *bla*_{CMY} and ISEcp1 probes with chromosomal DNA digested with EcoRI and HindIII restriction enzymes (MBI Fermentas, Vilnius, Lithuania), as described previously (21). The *bla*_{CMY} (1,143-bp) and ISEcp1 (181-bp) probes were obtained by amplifying DNA from isolate PL 1662/00 with the primer pairs ampC1/ampC2 and ecpF2/ecpR1 (Table 2), respectively. Chromosomal versus plasmidic localization of *bla*_{CMY} genes was assessed by I-CeuI analysis (22), as described previously (9).

Partial cloning and sequencing of ISEcp1-*bla*_{CMY} modules. DNA from all Polish and French isolates was digested with EcoRI and HindIII, and ligated into plasmid pHSG398 (33). *E. coli* DH5 α electroporants were selected with 2 μ g of cefotaxime/ml and 25 μ g of chloramphenicol/ml (Sigma-Aldrich, St. Louis, MO). Recombinant plasmids were checked for inserts of ~4.2 kb ("main *bla*_{CMY} locus") and ~3.1 kb ("additional *bla*_{CMY} locus"). Sequencing of the inserts was performed using primers specific for insert-flanking vector sequences, ISEcp1 and *bla*_{CMY}s (Table 2), and other primers designed according to the accumulating sequence. Sequences were analyzed with the DNASTAR Lasergene software (Madison, WI).

Characterization of entire ISEcp1-*bla*_{CMY} modules and their chromosomal insertion site: "main locus." The structure and site of integration of ISEcp1-*bla*_{CMY} transposition modules within the *P. mirabilis* chromosome at the "main locus" was initially investigated by inverse PCR. Total DNA (1 μ g) of isolate IT NO-051/03 was digested by AgeI (New England Biolabs, Inc., Beverly, MA). The digestion mixture, purified with the Wizard SV Gel and PCR Cleanup system (Promega, Madison, WI), was diluted 1:10 and then self-ligated by using T4 DNA ligase (Promega). The ligation mixture (2 μ l) was then used in a PCR with the primers blcF and C12-tnpA/r (7) (Table 2) to amplify the adjacent regions of the ISEcp1-*bla*_{CMY} module. Sequences flanking the module were compared to the genomic sequence of *P. mirabilis* strain HI4320 (GenBank accession no. AM942759) (28), using the microbial BLAST tool (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). For the remaining isolates, the module structure and the integration site were analyzed by PCR mapping using primers targeting various regions (Table 2 and Fig. 1), designed based on sequences of the inverse PCR product and the *P. mirabilis* HI4320 locus *pepQ* (positions 3872453 to 3873787) (28).

TABLE 2. Oligonucleotides used in this study

Primer	Gene	Oligonucleotide sequence (5'–3')	Position ^a	Purpose	Source or reference
ampC1	<i>bla</i> _{CMY}	ATG ATG AAA AAA TCG TTA TGC	1–21*	PCR, sequencing	11
ampC2	<i>bla</i> _{CMY}	TTG CAG CTT TTC AAG AAT GCG C	1122–1143*	PCR, sequencing	11
ampC5	<i>bla</i> _{CMY}	CAG CGT TTG CTG CGT G	222–237*	PCR, sequencing	This study
E4/F	<i>bla</i> _{CMY}	TGG GTT CAG GCC AAC ATG GAT GC	757–779*	PCR mapping, sequencing	This study
E7/R	<i>bla</i> _{CMY}	TGC CAG CAT CAC GAT GCC AAG G	1059–1080*	PCR mapping, sequencing	This study
ecpF2	3' end of <i>ISEcp1</i>	GTT GCT CTG TGG ATA ACT TG	2084–2102†	PCR, sequencing	39
ecpR1	<i>ISEcp1</i>	CCT AAA TTC CAC GTG TGT	2247–2264†	PCR	This study
ISEcp1/F	<i>tnpA</i> of <i>ISEcp1</i>	CAT GCT CTG CGG TCA CTT C	959–977†	PCR mapping	This study
E8/F	Downstream of <i>bla</i> _{CMY}	CCA GGA TAT TGG GCC TC	3534–3550†	PCR mapping	This study
blc/R	<i>blc</i>	GAC AAC CAG GAA TGC AGC	3647–3664†	PCR mapping	This study
sugE/R	<i>sugE</i>	GCC TGA TAT GTC CTG GAT CGT	4448–4468†	PCR mapping	This study
ORF6/R	<i>orf6</i>	CTT CAT CCC TAT CAT CGC CA	5634–5653†	PCR mapping	This study
ORF6e/R	<i>orf6</i>	AAT CAG CAA TAA CAT CAC CAT G	5770–5791†	PCR mapping	This study
mobB/R	<i>mobB</i>	TAG AGC AGC AGA AGC CAG CT	6205–6224†	PCR mapping	This study
RNAIip/R	RNAII	TCA TTC CAC GCC TGA CAC TC	6741–6760†	PCR mapping	This study
pepQ/F	<i>pepQ</i>	CAC CTG TTG ATT ATT GGC AT	3872704–3872723‡	PCR mapping, sequencing	This study
pepQ/R	<i>pepQ</i>	TCA GGC TAA ATG TAA GTC TC	3873769–3873787‡	PCR mapping, sequencing	This study
blc/F	<i>blc</i>	CTG TGG ATC CTT TCA CGG A	4025–4043†	Inverse PCR	This study
C12-tnpA/r	<i>tnpA</i> of <i>ISEcp1</i>	TAT TCT GAA GAG TCC AAG GAA	1921–1901†	Inverse PCR	6
ppiD/F	Intergenic region PMI0120/ <i>ppiD</i>	GCG ATT ACT GAA TGC CAT C	150710–150692‡	PCR mapping, sequencing	This study
ppiD/R	<i>ppiD</i>	CAA CGG CAG AAC AGC TTG	150366–150383‡	PCR mapping, sequencing	This study

^a *, Position numbering is according to the first nucleotide of the coding sequence of the *bla*_{CMY} gene; †, position numbering is according to the sequence of plasmid pH 205 (GenBank acc. no. EU331426) (39); ‡, position numbering is according to the sequence of the *P. mirabilis* HI4320 genome (GenBank accession no. AM942759) (28).

Analysis of the insertion site for *ISEcp1*-*bla*_{CMY} modules: “additional locus.” Sequences 3' to the *ISEcp1*-*bla*_{CMY} modules of the “additional locus,” determined by sequencing of cloned fragments, were compared to the genomic sequence of *P. mirabilis* HI4320 (28). The matching sequence of the *ppiD* region was then used to design primers for mapping the modules in the spacer between the *ppiD* gene (positions 148619 to 150496) and the PMI0120 open reading frame (ORF; 150751 to 151125) (Table 2 and Fig. 1) and for sequencing the 5' junction.

Molecular typing. Ribotyping was performed after HincII (New England Biolabs) digestion of genomic DNA, as described by Pignato et al. (30). For PFGE, total *P. mirabilis* DNA in agarose plugs was prepared as described previously (8), digested with NotI and SfiI (New England Biolabs), and electrophoresed using a CHEF III Bio-Rad apparatus (Hercules, CA). All electrophoretic patterns were analyzed using GelCompar v4.1 (Applied Maths NV, Sint-Martens-Latem, Belgium), using the Dice coefficient and clustering by UPGMA (unweighted pair-group method with arithmetic averages), with 1% tolerance in band position differences. For the NotI+SfiI PFGE patterns, a similarity cutoff of 80% was applied for discerning clusters of related isolates (31).

Antimicrobial susceptibility testing. The MICs of β-lactams were evaluated by the agar dilution method according to Clinical and Laboratory Standards Institute criteria (6). For the isolates tested earlier, the methodology was described in previous reports (9, 11, 21, 23, 25, 35).

Nucleotide sequence accession numbers. Sequences of the *bla*_{CMY-45} gene coding region and of the Tn6113 (*bla*_{CMY-12}) and Tn6093 (*bla*_{CMY-16}) modules will appear in the EMBL database under accession numbers FN546177, FR716828, and FM995219, respectively.

RESULTS

Sequence and location of the *bla*_{CMY} genes in *P. mirabilis* isolates. A total of 21 *P. mirabilis* isolates producing CMY-2-like β-lactamases from different countries and periods were investigated (Table 1). The sequences of the *bla*_{CMY} genes were already known in five isolates from Poland (*bla*_{CMY-4}, *bla*_{CMY-12}, *bla*_{CMY-14}, *bla*_{CMY-15}, and *bla*_{CMY-38}), five isolates from Italy (*bla*_{CMY-16}), and three isolates from France (although from patients of Greek and Algerian origins [*bla*_{CMY-4} and *bla*_{CMY-12}, respectively]) (9, 11, 13, 21, 23). PCR and

sequencing showed that the remaining eight isolates carried either *bla*_{CMY-16} (the recent isolates from Greece and the IT LC-10/08 isolate from Italy) or a new allele (the PL 1376/00 isolate from Poland), named *bla*_{CMY-45}, which differs from *bla*_{CMY-2} (2) by four point mutations: C₄₁₈A (Gln140Lys), G₅₁₁T (Ala171Ser), T₆₆₁C (Trp221Arg), and G₁₀₁₉T (Gly340Val).

Comparison to other known *bla*_{CMY-2}-like alleles indicated that those carried by our *P. mirabilis* isolates form a distinct cluster of more closely related sequences (Fig. 2). Sequence comparisons also suggested that the present study's alleles may have evolved from *bla*_{CMY-4} by stepwise mutations; *bla*_{CMY-12} was notable in that it shared, on the one hand, the G₅₁₁T (Ala171Ser) mutation with *bla*_{CMY-16} and *bla*_{CMY-45}, and, on the other, the G₁₀₈₈A (Ser363Asn) mutation with *bla*_{CMY-15} and *bla*_{CMY-38} (Fig. 2B).

I-CeuI analysis proved (or confirmed) that the *bla*_{CMY} genes were chromosome-borne in all studied isolates (data not shown). PCR and sequencing assays revealed (or confirmed) the presence of an *ISEcp1* element inserted 110bp upstream of the *bla*_{CMY} genes in all isolates (thus correcting the value of 106 bp previously published for *bla*_{CMY-4}, *bla*_{CMY-12}, *bla*_{CMY-14}, and *bla*_{CMY-15} [21]). Southern blot experiments carried out with genomic DNAs digested with EcoRI (which cuts inside *ISEcp1*) and HindIII (which does not cut inside either *ISEcp1* or any of the *bla*_{CMY}s) and using either a *bla*_{CMY} or a *ISEcp1* probe yielded a hybridizing band of ~4.2 kb with all isolates (“main *bla*_{CMY} locus”) and another band of ~3.1 kb with the isolates carrying *bla*_{CMY-12}, *bla*_{CMY-15}, and *bla*_{CMY-38} (“additional *bla*_{CMY} locus”). These results revealed (or confirmed) that, while in most isolates the *bla*_{CMY} gene was present in a single copy, two copies were present in isolates with *bla*_{CMY-12},




FIG. 1. Schematic representation of *ISEcp1* transposition modules containing the *C. freundii*-derived *bla*_{CMY} genes, enzyme restriction sites, and primer hybridization sites used in the analysis of the Tn6093 and Tn6113 structures. (A) Tn6114 module present in the pH 205 plasmid; (B) Tn6093 module inserted into the *P. mirabilis pepQ* gene ("main locus"); (C) Tn6113 module inserted between *ppiD* and PMI0120 ORF in the *P. mirabilis* chromosome ("additional locus"). The schemes are aligned according to the *ISEcp1* position. EcoRI and HindIII sites, used in cloning experiments, are indicated by dashed vertical lines. Black arrows below the Tn6093 and Tn6113 schemes represent primers used for PCR mapping and sequencing.

*bla*_{CMY-15}, and *bla*_{CMY-38} from Poland and France (Algeria) (21).

Genetic context of the *bla*_{CMY} genes and their integration sites. The genetic context of the *bla*_{CMY} genes and their integration sites were investigated by a combination of cloning, inverse PCR, and PCR mapping and sequencing, as detailed in Materials and Methods. The results showed that all of the isolates carried variants of a 6,210-bp *ISEcp1-bla*_{CMY} module, named Tn6093, integrated into the *P. mirabilis pepQ* gene coding for Xaa-Pro dipeptidase (28). In all isolates, Tn6093 was inserted in the same position within *pepQ* and was flanked by 5-bp direct repeats (AATCA), indicating that the *ISEcp1*-mobilized module had integrated by transposition into the *P. mirabilis* chromosome. Tn6093 contained *ISEcp1*, followed by the *C. freundii*-derived *bla*_{CMY}, *blc*, and *sugE* genes, a part of the ColE1-type plasmid backbone (regions *orf6*, *mobB*, and Δ RNAII), and terminating with an *ISEcp1* IRR-like sequence, named IRR-4 (Fig. 1). Tn6093 matched very well fragments of plasmids pTKH11, pA172, and pH 205 with *ISEcp1* modules called Tn6114, carrying complete *bla*_{CMY}, *blc*, and *sugE* genes and terminating with the IRR-like motif IRR-3 (Fig. 1) (38, 39). Compared to the homologous part of pH 205 (39), the Tn6093 variants had, apart from variable mutations within

*bla*_{CMY}s, eight stable single nucleotide polymorphisms: one between *ISEcp1* and *bla*_{CMY} and seven downstream of Tn6114. The Tn6093-containing locus gave rise to the ~4.2-kb band ("main *bla*_{CMY} locus") recognized in Southern blot experiments with all *P. mirabilis* isolates.

In the isolates with two *bla*_{CMY} copies, a second *ISEcp1-bla*_{CMY} module, 3,783 bp long and named Tn6113, was inserted into the *P. mirabilis* intergenic spacer between ORF PMI0120 and the *ppiD* gene encoding peptidyl-prolyl *cis-trans* isomerase D (28). In all of these isolates, Tn6113 was inserted at the same position, 154 bp downstream of *ppiD*, and was flanked by 5-bp direct repeats (TATGA), which indicated that this module also had integrated into the chromosome by transposition. Tn6113 consisted of *ISEcp1*, followed by the *C. freundii*-like sequences *bla*_{CMY}, *blc*, and Δ *sugE*, and terminating with an IRR-like motif inside *sugE*, named IRR-2 (Fig. 1). Therefore, Tn6113 was shorter by 247 bp than Tn6114. The Tn6113-containing locus gave rise to the ~3.1-kb band ("additional *bla*_{CMY} locus") identified in Southern blot experiments with the *P. mirabilis* isolates carrying two *bla*_{CMY} copies; the same *bla*_{CMY} allele was always present in both Tn6093 and Tn6113 modules.




FIG. 2. Sequence comparison of *bla*_{CMY-2}-like genes. (A) Dendrogram of all mobile *bla*_{CMY-2}-like gene sequences obtained with the MEGA v3.1 software (19); (B) consensus network of the *bla*_{CMY-2}-like genes located in *ISEcp1* modules with a 110-bp distance between *ISEcp1* and *bla*_{CMY} (plasmidic Tn6114-like, and *P. mirabilis* Tn6093-like modules). The consensus network was generated with the SplitsTree 4.10 software (17), after prealignment in Mauve 2.3.0 (10) and analysis by the CloneFrame 1.1 software (12).

Clonality of the *bla*_{CMY}-carrying *P. mirabilis* isolates. Given the identical structures and insertion sites of *bla*_{CMY}-carrying elements, we investigated the possible clonality of *P. mirabilis* chromosomes using ribotyping and PFGE of genomic DNA after NotI-SfiI digestion. All *bla*_{CMY}-carrying isolates belonged to three ribotypes. The main one, R5, grouped 18 isolates, while the remaining three isolates belonged to two other ribotypes (R6, $n = 1$; R7, $n = 2$). In contrast, the six *bla*_{CMY}-negative control isolates tested, belonged to four distinct ribotypes, R1 to R4 (Fig. 3). As expected, PFGE profiling resulted in a somewhat higher discrimination, nevertheless confirming the considerable relatedness of *bla*_{CMY}-positive isolates compared to that of *bla*_{CMY}-negative ones (Fig. 3). Clonal relationships similar to those revealed by ribotyping were also obtained when the I-CeuI typing patterns were compared, as expected, given that this enzyme cuts within *rrn* loci (data not shown).

Antimicrobial susceptibility testing. The β -lactam resistance patterns of the study isolates were typical as for producers of CMY-type cephalosporinases (1, 21, 29), with high-level resistance to penicillins, cefoxitin, cefotaxime, and ceftazidime (Table 3). However, there were significant differences in resistance levels, even among the isolates that produced the same enzyme variant, and this variation concerned both the compounds that are substrates of CMY-like β -lactamases and those that are not (for imipenem, the presence of metallo- β -lactamase VIM-1 in the isolates from Greece was noteworthy). Although high, the MICs for the isolates with double *bla*_{CMY} gene copies were not consistently higher than those for the isolates with single *bla*_{CMY} copies.

DISCUSSION

This study follows several reports on the international presence of unusual *P. mirabilis* strains with chromosomal *bla*_{CMY-2}-like genes. Such isolates were first recovered in the 1990s in France, some of them from Greek and Algerian patients (4, 11); further studies revealed their emergence and spread in Poland (13, 21) and, more recently, in Italy (9, 23) and Greece (25, 35). Comparative analysis of representative isolates from all of the above countries revealed striking similarities among them, regardless of geographic and temporal origins. First, their *bla*_{CMY} genes resided in transposition modules of the same structure, called Tn6093, and composed of *ISEcp1*, the *C. freundii* chromosomal fragment and a part of the ColE1-type plasmid backbone. Second, Tn6093 elements in all isolates were integrated into the same site of the *P. mirabilis* chromosomal *pepQ* gene (28). These data are consistent with a single mobilization of these *bla*_{CMY} genes' ancestor and identified its putative donor to the *P. mirabilis* chromosome. This was most probably a ColE-like plasmid similar to pTKH11, pA172, and pH 205, all of which carry an *ISEcp1* module with *bla*_{CMY-2}-like genes, named Tn6114 (38, 39). Tn6114-like elements, extended by plasmid scaffold sequences, formed the Tn6093 modules. During the putative mobilization-transfer-integration, *ISEcp1* would have utilized different alternative IRRs while transposing from the *C. freundii* chromosome to the plasmid (IRR-3) and then from the plasmid to the *P. mirabilis* chromosome (IRR-4), thus giving rise to the Tn6114- and Tn6093-like structures, respectively.

In sequence comparisons, the *P. mirabilis* *bla*_{CMY} alleles




FIG. 3. Dendrogram based on NotI+SfiI PFGE patterns, indicating clusters of the resulting types, as well as ribotypes. The bands arising after NotI+SfiI PFGE for each isolate are shown. The number next to the isolate code denotes the CMY variant. PFGE type clusters (>80% similarity, as per the percent scale at top left) are labeled A to E; ribotypes 1 to 7 are shown to the right of these.

formed a distinct cluster among all *bla*_{CMY-2}-like genes. This lends further support to the hypothesis of a single mobilization-transfer-integration event, as posited by the data just discussed: according to this, the seven *bla*_{CMY} alleles studied here will have evolved by the stepwise acquisition of mutations after Tn6093 chromosomal integration. Allele *bla*_{CMY-12}, since it shares polymorphisms specific to two separate gene sublineages, may have arisen from recombination between two different alleles. Most of the *bla*_{CMY} genes identified in the *P. mirabilis* chromosome have only been observed in this genetic environment thus far. Their direct precursor is likely to have been *bla*_{CMY-4}, identified in early isolates from France/Greece and Poland (although not in a plasmidic Tn6114-like module), rather than the *bla*_{CMYs} (*bla*_{CMY-5}, *bla*_{CMY-31}, and *bla*_{CMY-36}) of the ColE1-like plasmids described to date (38, 39), which all have higher numbers of nucleotide differences. Moreover, several other polymorphisms have been detected between Tn6093 and the homologous parts of these plasmids. As has been shown in earlier studies on recombinant *E. coli* expressing most of the *bla*_{CMY} genes studied here, mutations acquired during these genes' evolution were neutral (9, 21); however, the clinical *P. mirabilis* strains themselves varied in resistance levels to β -lactams (9, 21, 23, 25, 35) (Table 3). Such variation could be due to other enzymes, as in the case of the Greek isolates, which produced VIM-1 metallo- β -lactamase (25, 35) (Table 1), or to nonenzymatic mechanisms, e.g., reduction in permeability, as previously proposed (21).

The presence of a second *bla*_{CMY} module in a subset of our isolates was also intriguing. Previously, Polish isolates had been found to contain two copies of *bla*_{CMY-12} and *bla*_{CMY-15} (21). The present study, while confirming these observations, also showed that the French-Algerian isolate with *bla*_{CMY-12} (11) and the Polish one with *bla*_{CMY-38} (13) also had two gene copies. These "duplicated" alleles are related: within the *bla*_{CMY} sequence cluster, *bla*_{CMY-15} and *bla*_{CMY-38} form a sublineage, to which *bla*_{CMY-12} is closely linked (Fig. 2). All "additional *bla*_{CMY} loci" contained an identical *ISEcp1* module, Tn6113, inserted into the same site, downstream of the *ppiD* gene (28). Most probably, this emerged from a transposition event in which *ISEcp1* utilized yet another IRR-like motif (IRR-2); however, it is impossible to decide on whether Tn6113 resulted from a "main *bla*_{CMY} locus" Tn6093 or a plasmidic Tn6114 transposition. At any rate, this integration also probably occurred once, at the origin of the specific sublineage of *bla*_{CMYs}. Interestingly, the Tn6093 and Tn6113 found in the same chromosome always harbored identical *bla*_{CMY} variants, possibly due to sequence homogenization by a gene-conversion-like mechanism. As reported previously, isolates with double *bla*_{CMY} copies did not show consistently higher β -lactam resistance levels compared to single-copy isolates (21) (Table 3). This might again have resulted from the already mentioned contributions of β -lactamase- and non- β -lactamase-mediated mechanisms alike on overall resistance.

Addressing the possible clonality of the *bla*_{CMY}-carrying iso-

TABLE 3. β-Lactam susceptibility of the study *P. mirabilis* isolates

Isolate	Major β-lactamase(s)	MIC (μg/ml) ^a										Source or reference
		AMP/AMX	PIP	TZP	CTX	CAZ	FEP	FOX	ATM	IPM		
Clinical <i>P. mirabilis</i> isolates ^b												
PL 6735/99	CMY-14	>512	128	8	64	128	32	128	16	2	21	
PL 1662/00	CMY-15	>512	256	32	128	128	8	512	8	16	21	
PL 27/00	CMY-12	>512	256	32	64	128	16	256	8	4	21	
PL 1376/00	CMY-45	>512	256	16	64	128	4	128	8	2	This study	
PL 864/01	CMY-4	>512	128	1	32	16	4	64	0.5	2	21	
PL 1455/04	CMY-38	>512	128	32	>128	64	16	128	8	2	This study	
IT NO-051/03	CMY-16	>128	64	4	64	32	2	32	1	2	9	
IT VA-1017/03	CMY-16	>128	64	4	>128	32	2	32	1	2	9	
IT VA-832/05	CMY-16	>128	>128	4	>128	32	2	64	2	4	23	
IT VA-070/06	CMY-16	>128	>128	2	128	16	2	32	1	2	23	
IT VA-414/06	CMY-16	>128	>128	2	128	16	2	32	1	2	23	
IT LC-10/08	CMY-16	>128	>128	4	128	32	4	32	2	2	This study	
GR 17/04	CMY-16 + VIM-1	>128	>128	16	>128	32	4	32	2	2	35	
GR 15184/05	CMY-16 + VIM-1	>128	>128	16	128	32	8	>128	2	2	35	
GR 15315/05	CMY-16 + VIM-1	>128	>128	32	>128	32	16	>128	2	4	35	
GR 2506/07	CMY-16 + VIM-1	>128	>128	64	>128	128	16	>128	8	8	This study	
GR 2530/07	CMY-16 + VIM-1	>128	>128	64	128	64	4	>128	4	4	This study	
GR 2720/08	CMY-16 + VIM-1	>128	>128	16	>128	128	16	>128	4	8	25	
22317	CMY-4	>128	64	2	64	32	0.125	32	1	1	11	
PLAR	CMY-4	>128	128	4	128	64	0.25	128	1	1	11	
34955	CMY-12	>128	32	2	>128	>128	0.25	128	2	0.5	11	
ATCC isolates												
<i>E. coli</i> ATCC 25922		4	1	0.5	0.03	0.25	0.125	8	0.125	0.06	21	
<i>P. mirabilis</i> ATCC 7002		1	≤0.25	≤0.25	≤0.015	0.06	0.125	2	≤0.015	0.5	21	

^a Abbreviations: AMP, ampicillin; AMX, amoxicillin; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; FOX, ceftoxitin; IPM, imipenem; PIP, piperacillin; TZP, piperacillin + tazobactam. For AMP/AMX, PIP, and FOX, different highest concentrations of the compounds were used in the MIC determinations in the three laboratories participating in the study (512 or 128 μg/ml). For TZP, the tazobactam concentration was 4 μg/ml.

^b Most of the isolates were obtained from Poland (PL), Italy (IT), and Greece (GR). Isolates 22317 and PLAR originated also from Greece. Isolate 34955 originated from Algeria.

lates required a method able to assess phylogenetic similarity among organisms collected over a large geographic area and a long period of time. Therefore, in the absence of an MLST scheme for *P. mirabilis*, we used ribotyping. This revealed a significant relatedness among most of our isolates, especially compared to a group of random *bla*_{CMY}-negative *P. mirabilis* strains. In general, these results were congruent with those obtained with the more discriminatory, PFGE-based methods (using either I-Ceu-I-digested or NotI-SfiI-digested genomic DNA).

The present study indicates a common origin of *P. mirabilis* strains with acquired and chromosomally inserted *bla*_{CMY-2}-like genes, spreading in Europe since the 1990s. Their dissemination is probably quite efficient: in Poland, such isolates comprised ~20% of the nosocomial *P. mirabilis* isolates in the mid-2000s (13), while in Italy their progressive spread has also been documented (9, 23). It is therefore likely that they represent a true international clonal group of *P. mirabilis* undergoing continuous diversification over time and place.

ACKNOWLEDGMENTS

We are grateful to Guillaume Arlet for the *P. mirabilis* strains 22317, PLAR, and 34955 and to Joanna Empel for helpful discussions.

This study was supported in part by grants from the European Commission (TROCAR contract HEALTH-F3-2008-223031 and TEMPOTest-QC contract HEALTH-F3-2009-241742) and by the grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education.

REFERENCES

1. Barlow, M., and B. G. Hall. 2002. Origin and evolution of the AmpC β-lactamases of *Citrobacter freundii*. *Antimicrob. Agents Chemother.* **46**:1190–1198.
2. Bauernfeind, A., I. Stemplinger, R. Jungwirth, and H. Giamarellou. 1996. Characterization of the plasmidic β-lactamase CMY-2, which is responsible for cephamycin resistance. *Antimicrob. Agents Chemother.* **40**:221–224.
3. Beceiro, A., and G. Bou. 2004. Class C β-lactamases: an increasing problem worldwide. *Rev. Med. Microbiol.* **15**:141–152.
4. Bret, L., et al. 1998. Chromosomally encoded AmpC-type β-lactamase in a clinical isolate of *Proteus mirabilis*. *Antimicrob. Agents Chemother.* **42**:1110–1114.
5. Bush, K., and G. A. Jacoby. 2010. Updated functional classification of β-lactamases. *Antimicrob. Agents Chemother.* **54**:969–976.
6. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. CLSI M100-S20U. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Colinon, C., V. Miriagou, A. Carattoli, F. Luzzaro, and G. M. Rossolini. 2007. Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 β-lactamases. *J. Antimicrob. Chemother.* **60**:258–262.
8. Daikos, G. L., et al. 2007. *Enterobacteriaceae* bloodstream infections: presence of integrons, risk factors, and outcome. *Antimicrob. Agents Chemother.* **51**:2366–2372.
9. D’Andrea, M. M., et al. 2006. CMY-16, a novel acquired AmpC-type β-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of *Proteus mirabilis* from northern Italy. *Antimicrob. Agents Chemother.* **50**:618–624.
10. Darling, A. C. E., B. Mau, F. R. Blattner, and N. T. Perna. 2004. Mauve: multiple alignment of conserved genomic sequence with rearrangements. *Genome Res.* **14**:1394–1403.
11. Decré, D., et al. 2002. Characterization of CMY-type β-lactamases in clinical strains of *Proteus mirabilis* and *Klebsiella pneumoniae* isolated in four hospitals in the Paris area. *J. Antimicrob. Chemother.* **50**:681–688.
12. Didelot, X., and D. Falush. 2007. Inference of bacterial microevolution using multilocus sequence data. *Genetics* **175**:1251–1266.
13. Empel, J., et al. 2008. Molecular survey of β-lactamases conferring resistance to newer β-lactams in *Enterobacteriaceae* isolates from Polish hospitals. *Antimicrob. Agents Chemother.* **52**:2449–2454.

14. Giles, W. P., et al. 2004. DNA sequence analysis of regions surrounding *bla*_{CMY-2} from multiple *Salmonella* plasmid backbones. *Antimicrob. Agents Chemother.* **48**:2845–2852.
15. Hopkins, K. L., M. J. Batchelor, E. Liebana, A. P. Deheer-Graham, and E. J. Threlfall. 2006. Characterisation of CTX-M and AmpC genes in human isolates of *Escherichia coli* identified between 1995 and 2003 in England and Wales. *Int. J. Antimicrob. Agents* **28**:180–192.
16. Hopkins, K. L., et al. 2006. Replicon typing of plasmids carrying CTX-M or CMY β -lactamases circulating among *Salmonella* and *Escherichia coli* isolates. *Antimicrob. Agents Chemother.* **50**:3203–3206.
17. Huson, D. H., and D. Bryant. 2006. Application of phylogenetic networks in evolutionary studies. *Mol. Biol. Evol.* **23**:254–267.
18. Jacoby, G. A. 2009. AmpC β -lactamases. *Clin. Microbiol. Rev.* **22**:161–182.
19. Kumar, S., M. Nei, J. Dudley, and K. Tamura. 2008. MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences. *Brief Bioinform.* **9**:299–306.
20. Lartigue, M. F., L. Poirel, D. Aubert, and P. Nordmann. 2006. In vitro analysis of *ISEcp1B*-mediated mobilization of naturally occurring β -lactamase gene *bla*_{CTX-M} of *Kluyvera ascorbata*. *Antimicrob. Agents Chemother.* **50**:1282–1286.
21. Literacka, E., et al. 2004. Four variants of the *Citrobacter freundii* AmpC-type cephalosporinases, including two novel enzymes, CMY-14 and -15, in a *Proteus mirabilis* clone widespread in Poland. *Antimicrob. Agents Chemother.* **48**:4136–4143.
22. Liu, S. L., A. Hessel, and K. E. Sanderson. 1993. Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for rRNA, in *Salmonella* spp., *Escherichia coli*, and other bacteria. *Proc. Natl. Acad. Sci. U. S. A.* **90**:6874–6878.
23. Luzzaro, F., et al. 2009. Spread of multidrug-resistant *Proteus mirabilis* isolates producing an AmpC-type β -lactamase: epidemiology and clinical management. *Int. J. Antimicrob. Agents* **33**:328–333.
24. Miriagou, V., A. Carattoli, E. Tzelepi, L. Villa, and L. S. Tzouveleki. 2005. IS26-associated In4-type integrons forming multiresistance loci in enterobacterial plasmids. *Antimicrob. Agents Chemother.* **49**:3541–3543.
25. Miriagou, V., et al. 2010. Detecting VIM-1 production in *Proteus mirabilis* by an imipenem-dipicolinic acid double disk synergy test. *J. Clin. Microbiol.* **48**:667–668.
26. Nakano, R., R. Okamoto, N. Nagano, and M. Inoue. 2007. Resistance to gram-negative organisms due to high-level expression of plasmid-encoded *ampC* β -lactamase *bla*_{CMY-4} promoted by insertion sequence *ISEcp1*. *J. Infect. Chemother.* **13**:18–23.
27. Nakano, R., et al. 2004. CFE-1, a novel plasmid-encoded AmpC β -lactamase with an *ampR* gene originating from *Citrobacter freundii*. *Antimicrob. Agents Chemother.* **48**:1151–1158.
28. Pearson, M. M., et al. 2008. Complete genome sequence of uropathogenic *Proteus mirabilis*, a master of both adherence and motility. *J. Bacteriol.* **190**:4027–4037.
29. Philippon, A., G. Arlet, and G. A. Jacoby. 2002. Plasmid-determined AmpC-type β -lactamases. *Antimicrob. Agents Chemother.* **46**:1–11.
30. Pignato, S., G. M. Giammanco, F. Grimont, P. A. Grimont, and G. Giammanco. 1999. Molecular characterization of the genera *Proteus*, *Morganella*, and *Providencia* by ribotyping. *J. Clin. Microbiol.* **37**:2840–2847.
31. Struelens, M. J., V. Schwam, A. Deplano, and D. Baran. 1993. Genome macrorestriction analysis of diversity and variability of *Pseudomonas aeruginosa* strains infecting cystic fibrosis patients. *J. Clin. Microbiol.* **31**:2320–2326.
32. Su, L. H., et al. 2006. Distribution of a transposon-like element carrying *bla*_{CMY-2} among *Salmonella* and other *Enterobacteriaceae*. *J. Antimicrob. Chemother.* **57**:424–429.
33. Takeshita, S., M. Sato, M. Toba, W. Masahashi, and T. Hashimoto-Gotoh. 1987. High-copy-number and low-copy-number plasmid vectors for *lacZ* α -complementation and chloramphenicol or kanamycin resistance selection. *Gene* **61**:63–74.
34. Verdet, C., G. Arlet, G. Barnaud, P. H. Lagrange, and A. Philippon. 2000. A novel integron in *Salmonella enterica* serovar Enteritidis, carrying the *bla*_{DHA-1} gene and its regulator gene *ampR*, originated from *Morganella morganii*. *Antimicrob. Agents Chemother.* **44**:222–225.
35. Vourli, S., et al. 2006. Emergence of *Proteus mirabilis* carrying the *bla* metallo- β -lactamase gene. *Clin. Microbiol. Infect.* **12**:691–694.
36. Whichard, J. M., et al. 2007. Human *Salmonella* and concurrent decreased susceptibility to quinolones and extended-spectrum cephalosporins. *Emerg. Infect. Dis.* **13**:1681–1688.
37. Woodford, N., S. Reddy, E. J. Fagan, R. L., et al. 2007. Wide geographic spread of diverse acquired AmpC β -lactamases among *Escherichia coli* and *Klebsiella* spp. in the UK and Ireland. *J. Antimicrob. Chemother.* **59**:102–105.
38. Wu, S. W., K. Dornbusch, G. Kronvall, and M. Norgren. 1999. Characterization and nucleotide sequence of a *Klebsiella oxytoca* cryptic plasmid encoding a CMY-type β -lactamase: confirmation that the plasmid-mediated cephalosporinase originated from the *Citrobacter freundii* AmpC β -lactamase. *Antimicrob. Agents Chemother.* **43**:1350–1357.
39. Zioga, A., et al. 2009. CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. *Antimicrob. Agents Chemother.* **53**:1256–1259.